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DosimetryAbstract Purpose: To compare volumetric-modulated arc therapy (VMAT) with 3D-conformal
radiation therapy (3D-CRT) mediastinal irradiation for stage I–II supra-diaphragmatic Hodgkin’s
Lymphoma (HL).
Patients and methods: Eleven patients were planned for RT after 4–6 cycles of ABVD chemother-
apy: conventional 3D-CRT (AP/PA) and VMAT plans were conformed to the same PTV. Objective
was to choose the best PTV coverage plan with the least OAR dose. The 2 plans were compared for:
PTV coverage, mean dose and V5,V20lung, mean dose and V30heart, V5, V10, V15breast (female
patients), and the integral body dose.
Results: Both techniques achieved adequate PTV coverage. Mean lung and heart dose was consis-
tently lower in VMAT plans. The lung V20 dose was acceptable for VMAT, but exceeded the tol-
erance threshold in 6 cases with 3DCRT plans. A mean difference of 15.9% for both lungs V20
favored VMAT plans; average MLD difference was 2.3 Gy less for VMAT plans. Similarly, lower
maximum and mean heart doses with a 3.3 Gy dose reduction and a 9.4% difference in V30 favoredAl Kasr
banah),
(E.M.
164 C. Higby et al.VMAT plans. Mean V5lung/female breast and integral dose were invariably higher in VMAT plans
because of the low-dose spread.
Conclusions: VMAT is a valuable technique for treatment of large mediastinal HL. VMAT spares
the lung and heart compared to 3DCRT using ISRT in select HL cases. VMAT allows dose esca-
lation for post-chemotherapy residual disease with minimal dose to OARs. VMAT low radiation
dose (V5) to the normal tissues, and the increased integral dose should be considered.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Radiation therapy (RT) is the most effective single modality
for local control in Hodgkin’s Lymphoma (HL), and is com-
monly used as a component of combined modality therapy
(CMT) in many patients. Guidelines have been developed to
address the use of RT in the modern era of CMT, moving from
extended ﬁeld (EF) to involved-ﬁeld RT (IFRT), and more
recently to involved-site RT (ISRT), using 3D-CRT planning
and other advanced techniques such as intensity modulated
RT (IMRT), Rapidarc (RA), and optimized volumetric mod-
ulated arc therapy (VMAT) for treatment delivery [1–3]. 3D-
CRT generated AP/PA ﬁeld plan, with ﬁeld-in-ﬁeld compensa-
tion for dose homogeneity still remains the standard tech-
niques in many patients. There are situations where complex
anatomy and tumor location make IMRT and VMAT supe-
rior to conventional 3D-CRT techniques [4,5].
In this study, the intention was to explore the use of VMAT
in stage I–II patients with supra-diaphragmatic disease, partic-
ularly those presenting with large mediastinal disease volume,
with or without neck/axillary involvement, where the OAR
dose constraints cannot be met using the conventional 3D-
CRT.
Patients and methods
The whole cohort included 11 patients with mediastinal HL
with or without involvement of the neck/axilla. There were 4
females and 7 males. Three patients presented with mediastinal
disease only, and 8 with mediastinal, neck and/or axillary
involvement. Planning CT scan was acquired for the neck
and chest in contiguous 3 mm thickness slices on a Philips
large-bore CT simulator (Brilliance big bore V2.3.017184).
Patients were scanned in the supine position with the head
and shoulders immobilized in a thermoplastic shell. 4-D CT
sets were acquired in free breathing, deep inspiration and
expiration.
Contouring the target volumes (GTV, CTV, ITV and PTV)
were done based on the pre- and post-chemotherapy PET-CT
imaging according to the International Lymphoma Radiation
Oncology Group (ILROG) recommendations and guidelines
for involved-site irradiation (ISRT) [4]. Residual mediastinal
mass were localized as the post-chemo GTV. CTV included
the pre chemo GTV superior and inferior disease extension,
and edited for masses that initially encroached laterally on
the lungs, but regressed on chemotherapy. Internal target vol-
ume (ITV) was created on the free breathing CT, using the
information acquired from expiration and deep inspiration
CT scans, to account for respiratory movements. PTV was
then created by 1 cm margin isotropic expansion of the ITV,except for the neck nodal area where a 0.5 cm margin was used
for the CTV. The organs at risk were delineated (OARs: lungs,
heart, thyroid, salivary glands and spinal cord).
Patients included in this study had pathologically proven
HL stage IB-IIBX. All patients were treated using combined
modality treatment; 4 and 7 patients were treated by 4 and 6
cycles of ABVD (adriamycin, bleomycin, vinblastine, and
dacarbazine) chemotherapy regimen respectively. Nine and
two patients achieved complete (CR) and partial remission
(PR) respectively evidenced by PET-CT scans. Thereafter all
patients were treated by Involved Field RT (30.6 Gy/20
Fx/3.5 weeks for CR patients and 36 Gy/20 Fx/4 weeks for
PR ones).
VMAT plans were optimized using a complete 360 degree
arc or hemi-arcs or non-coplanar small arcs. The VMAT plans
were inversely planned using Pinnacle. Conventional RT
opposed AP/PA plans were generated using 3D-CRT, fash-
ioned to the same PTV in different clinical scenarios cases.
The primary objective was to identify for each case the tech-
nique which provides an adequate PTV coverage with the least
dose to the OARs.
For all patients, the resulting plans were normalized to a
prescribed dose of 30.6 Gy in 1.8 Gy fractions with 95% of
the dose to 100% of the PTV. Two patients had
post-chemotherapy metabolic residual disease and received
additional 6 Gy boost to the site of residual disease.
Dose-volume histograms (DVH) were used for evaluation
and estimation of OAR doses. Comparison was made between
3D-CRT and VMAT for PTV coverage, V5, V20 and mean
lung dose, as well as V30 heart, mean and maximum doses,
and the integral dose. In addition V5, 10, 15 and mean dose
to the breasts were estimated for female patients. Dose con-
straints to the heart, lungs and other OARs were deﬁned
according to the QUANTEC organ-speciﬁc dose/volume/out-
come data, based on the QUANTEC reviews guidelines [6].
Results
Dose-volume parameters and mean dose value statistics for
3D-CRT and VMAT plans for the complete cohort of 11
patients treated to the prescribed dose are displayed in Table 1.
The dose prescription was normalized to 30.6 Gy in all
cases except for two patients who had pot-chemotherapy resid-
ual active disease, where the dose was prescribed to 30.6 Gy
with an additional 5.4 Gy boost to area of residual disease
(total dose 36 Gy).
Homogeneous dose coverage of PTV was achieved in both
3D-CRT and VMAT plans, with 100% of PTV covered by at
least 95% of the dose (Fig. 1). Only in one case who presented
with bulky mediastinal disease, sub-pectoral and axillary
VMAT versus 3D-CRT in Hodgkin’s Lymphoma 165nodes, PTV coverage lower than the 95% dose normally
achieved was accepted because of the PTV-lungs overlap,
and the 95% coverage plan would have exceeded the lung
metrics.
The mean dose for lungs and heart was lower in VMAT
plans (Table 1). The V20 and mean dose to lungs were within
the acceptable range for VMAT, but exceeded the normal
acceptable levels for the 3D-CRT plans in 6 cases with bulky
mediastinal disease and/or sub-pectoral/axillary involvement.
For the whole cohort of patients, a mean difference ofTable 1 Dose-volume estimates and plan evaluation statistics for 3
Parameter 3D-CRT (mean) VMAT (mean)
Both lungs V20 35.4% 20.8%
V5 52.6% 67.8%
Mean 13 11.9
Right lung V20 36.7% 16.1%
V5 54.8% 68.7%
Mean 13.6 Gy 11.2 Gy
Left lung V20 38.5% 23.5%
V5 56.8 67%
Mean 14.3 Gy 12 Gy
Heart Max 33.1 Gy 31 Gy
Mean 15.8 Gy 12.8 Gy
V30 24.7% 17.7%
Body V5 23.3% 32.7%
V10 20.6% 20.5%
Right breast V5 4.6% 32.4%
V10 1.3% 11.2%
V15 0.5% 2.5%
Left breast V5 5.3% 39.5%
V10 4.5% 17.7%
V15 0% 4.8%
Figure 1 Same coverage using both 3D-CRT (a) and15.9% was noticed for V20 of both lungs in favor of VMAT.
The mean dose to both lungs was 2.3 Gy less for VMAT plans.
Similarly, maximum and mean doses to the heart were much
lower with VMAT; there was an average reduction of 3.3 Gy
of the mean heart dose and a 9.4% difference in V30 in favor
of VMAT plans. An illustrative DVH comparison for a female
patient is shown in Fig. 2. The mean V5breast and lung for the
whole cohort of patients was lower in the conventional plan,
because of the low-dose spread with VMAT (Fig. 3). Also,
the integral dose was invariably higher in the VMAT plans.D-CRT and VMAT plans.
Diﬀerence
Max diﬀ Minim diﬀ Mean diﬀ Median diﬀ
29.2% 8% 15.9% 14.5%
25.3% 0% 13% 12%
3.8 Gy 0.8 Gy 1.8 Gy 2.8 Gy
51.2% 2.7% 20.6% 16.4%
45.5% 14% 14% 12.2%
11.8 Gy 4.3 Gy 2.3 Gy 2.7 Gy
31% 1.4% 15% 13.9%
32.3% 1.4% 10.2% 6.6%
6 Gy 1.9 Gy 2.2 Gy 2.75 Gy
8.4 Gy 1.4 Gy 2.8 Gy 1.5 Gy
6.9 Gy 0.1 Gy 3.3 Gy 3 Gy
26% 0.5% 9.4% 5.3%
20.7% 1.4% 9.4% 10.3%
7.7% 7.1% 0% 0.5%
51.4% 12.5% 27.8% 19.4%
18.8% 1.1% 9.8% 11.8%
6.6% 0.8% 1.9% 0
61% 7.4% 34.1% 34%
31.3% 0% 13.2% 8.2%
14.3% 0% 4.8 Gy 0%
VMAT (b) in a female patient with HL stage IIA.
166 C. Higby et al.For the four female patients included in this cohort; the V5,
10, 15 to the breasts were compared in both techniques with a
higher dose for VMAT, particularly for patients in whom the
disease involved the hilar and/or subcarinal region (Fig. 3).
Hilar involvement and bulky disease at the mid-and lowerFigure 2 Dose volume histogram (DVH) and OARs for 3
Figure 3 Comparison between low dose spill for 3D-CRT (left) vs. V
for 3D-CRT vs. VMAT plans. (c) and (d) color wash of low dose lunlevels of mediastinum were however associated with unaccept-
able high doses to the lungs with 3D-CRT plans. For patients
with non-bulky superior anterior mediastinal disease, the low-
dose volume for lungs and both breasts was much lower for the
conventional plan as compared to VMAT (Fig. 3).D-CRT and VMAT for a female patient with HL IIb.
MAT (right) plans. (a) and (b) color wash of breasts low dose spill
gs (V5) for in 3D-CRT vs. VMAT plans.
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there was a better sparing of the parotid and thyroid with the
VMAT as compared with 3D-CRT. The two patients with
post-chemotherapy residual active disease, the total RT dose
was escalated to 36 Gy, and it showed that the 3DCRT was
associated with much higher V20 and mean dose to the lungs
and heart when compared to VMAT.Discussion
Radiation therapy is an integral component of combined
modality treatment (CMT) in HL. The RT delivery has
evolved over time, in an effort to reduce acute and long-term
toxicities while maintaining the excellent cure rate. Most of
HL cases can be managed with 3-DCRT using conventional
3D-CRT (AP/PA) techniques. This is particularly true in pedi-
atric and adolescent cases where the prescribed RT dose is in
the low range of 20–25 Gy. In adult HL however, RT standard
doses range between 30 and 36 Gy, except for a small subset of
patients with early-stage favorable HL where a lower dose of
20 Gy is used [1,7].
The conventional dose constraints used in treatment plan-
ning for most solid tumors do not appear to apply for lym-
phomas, since the relatively low RT doses needed in HL will
result in most treatment plans being within the acceptable lim-
its. However these may not constitute the optimal plan in
terms of keeping RT dose to the normal structures to a mini-
mum, in order to minimize the long-term toxicity. The RT ﬁeld
size was reduced over the last decades from extended ﬁeld
(EFRT) to involved-ﬁeld (IFRT), and involved-nodal radia-
tion (INRT), in an attempt to decrease the potential RT-
related toxicities. Based on clinical trials there is a general
agreement to replace EFRT with IFRT in the modern era of
CMT without compromising the outcome [8–10]. Recently,
the International Lymphoma Radiation Oncology Group
(ILROG) has developed guidelines for involved-ﬁeld site
(ISRT), since INRT may not be applicable in most clinical sce-
narios [4]. Nevertheless, there is still a wide variability between
the different centers as to the extent of RT ﬁeld applied in the
current clinical practice (INRT, IFRT, or ISRT). Moreover,
there is no agreement on the interpretation and implementa-
tion of ISRT, not only among different centers, but also
among the most expert radiation oncologists, as has been
shown in a recent ILROG study [11]. The choice of RT deliv-
ery technique depends on a number of factors: PTV coverage,
dose to OARs, tumor volume, shape and location in relation
to the individual anatomy, as well as patient gender and age
(children, young females with mediastinal and axillary dis-
ease). Different clinical scenarios dictate the dose-priorities
with respect to the OARs (co-existing morbid conditions: lung
disease, bleomycin toxicity, heart disease). Finally, the choice
of RT treatment technique largely depends on the treating
radiation oncologist’s expertise and the center’s experience.
A recent ILROG study showed that for the same set of case
clinical scenarios, the treatment technique and planning meth-
ods widely varied across the ILROG centers, techniques being
chosen according to the center’s best practice [12]. These vari-
ations must be undoubtedly even greater among centers across
the world.
In mediastinal disease close to the heart, the prescribed RT
doses may not be achievable with 3D-CRT without potentialsigniﬁcant lung and heart toxicity. This is particularly true in
cases presenting with bulky mediastinal disease and chest wall
or pericardial invasion. In these clinical situations, the conven-
tional 3D-CRT plan cannot deliver the required dose to the
PTV while meeting the OAR constraints because of the target
anatomy overlapping with OARs. The use of more complex
techniques such as optimized VMAT or IMRT allows dose
‘‘tailoring” and offers better sparing of the critical structures.
The trade-off with VMAT is that a larger volume of normal
tissues being exposed to low-dose RT [2,12,13]. This increased
low dose RT volume raises a major concern for a potential
increased risk of developing second malignant tumor (SMT),
especially breast cancer (BC) and thyroid cancer in female sur-
vivors [14–17]. In a recent study, optimized VMAT using non
co-planar arcs reduced the heart disease risk, as compared to
3D-CRT, with comparable estimated risks of thyroid and
breast cancer, but with an increase in lung cancer induction
probability [13]. The odds ratio for BC increases linearly with
RT dose and decreases with the use of smaller RT volumes
[13]; hence the importance of reducing RT dose and volume
in mediastinal irradiation, a ﬁnding which was proven in one
important study, where exclusion of axillae from supra-
diaphragmatic RT ﬁelds was associated with a substantial
reduction of Breast Cancer risk among females previously
reported with mantle ﬁelds [15].
In the current study, VMAT reduced the mean dose to
heart and lungs, V30heart and V20lungs, in all the resulting
plans. It was however associated with an increased volume
of the normal tissues receiving low-dose radiation, due to
delivery of highly conformal treatment through a rotational
geometry of 1 or 2 arcs or hemi-arcs, and to the increased mon-
itor units required for treatment delivery. Our data are compa-
rable to the dose estimate comparison for ten patients with
supra-diaphragmatic HL, planned using (3D CRT and
VMAT, INRT/ISRT) in ﬁve ILROG centers having vast expe-
rience in the treatment of lymphomas [11]. Also, the increase in
V5 and low-dose normal tissues with VMAT in the current
study was comparable to other reports from similar studies
[12,13,18–20].
Deep inspiration breath-hold (DBH) gadget is not available
at our center. Several studies have shown that DBH coupled
with VMAT, IMRT or 3D-CRT is associated with better spar-
ing of the heart and lungs than if the same techniques were
used alone [18].
In young female patients with disease limited to superior
anterior mediastinum, 3D-CRT plans could result in better
breast sparing as compared to VMAT. VMAT would give bet-
ter sparing of breast and lung when the disease extends to mid-
or lower mediastinum with hilar involvement. A ‘‘butterﬂy”
IMRT technique for mediastinal disease in young females
was developed in MD Anderson Cancer Center (MDACC)
[19]. This technique employs a special beam arrangement, daily
breath hold, and CT-on-rails veriﬁcation to achieve adequate
target coverage, while reducing the high- and low-dose radia-
tion exposure of the breasts and other critical organs. This
technique is only applicable to disease conﬁned to the medi-
astinum without any axillary involvement. Though the dose
to the breasts is lower, the V5lungs value for remains higher
for the ‘‘butterﬂy” as compared to 3DCRT AP/PA. VMAT
has the advantage of a shorter treatment time and faster treat-
ment delivery than IMRT. VMAT is also applicable in cases
with sub-pectoral and axillary involvement. Another new
168 C. Higby et al.alternative is proton therapy, though the role of proton has not
yet been deﬁned in HL, and it is not widely used because of the
treatment cost, complexity, and availability.
Conclusions
This study shows that VMAT is a valuable technique for treat-
ment of large mediastinal HL. It allows maximal lung and
heart sparing when compared to 3D-CRT in select Hodgkin
lymphoma patients treated with ISRT. In addition, it allows
dose escalation when needed, with minimal increased dose to
OARs. The main concern when using VMAT is the spreading
of low radiation dose to the normal tissue and hence an
increased integral dose. This raises concerns of possible
increased risk of Second malignancy, particularly breast cancer
when children and young female adolescent patients are trea-
ted. Long term data with regular follow up for treatment-
induced late toxicity is necessary before ﬁnal conclusions can
be made. ILROG guideline implementation and deﬁning crite-
ria for treatment plan evaluation for various clinical scenarios
will reﬁne radiation treatment, and will hopefully improve clin-
ical outcomes for patients.
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